All Updates

All Updates

icon
Filter
Partnerships
Median Technologies partners with a global oncology pharma for AI imaging biomarker discovery
Precision Medicine
Aug 6, 2024
This week:
Management news
6K Additive awarded project to develop C-103 powder for additive manufacturing
Additive Manufacturing
Sep 27, 2024
Partnerships
WAAM3D partners with Innovative Space Carrier, Cranfield University, and Aichi Sangyo for space transport development
Additive Manufacturing
Sep 19, 2024
Funding
INFINIT raises USD 6 million in funding to enhance infrastructure
Decentralized Finance (DeFi)
Yesterday
Product updates
Salesforce announces suite of AI-powered autonomous agent solutions
Workflow Automation Platforms
Yesterday
FDA approval
FDA approves Apple AirPods Pro as over-the-counter hearing aids
Age Tech
Yesterday
Partnerships
Paradigm Health and Sheba Medical partner to optimize clinical trials
Clinical Trial Technology
Yesterday
Funding
XP Health raises USD 33.2 million in Series B funding to expand vision care platform
Health Benefits Platforms
Yesterday
Product updates
Circle expands Web3 Services product suite to Arbitrum
Web3 Ecosystem
Yesterday
Management news
Exiger achieves FedRAMP Moderate Authorization for Federal Cloud
Supply Chain Tech
Yesterday
Product updates
Schouten Europe launches plant-based chicken schnitzel with new fiber technology
Plant-based Meat
Yesterday
Precision Medicine

Precision Medicine

Aug 6, 2024

Median Technologies partners with a global oncology pharma for AI imaging biomarker discovery

Partnerships

  • Median Technologies has announced a collaboration with a top 10 global oncology pharmaceutical firm on the application of AI to discover predictive imaging biomarkers that could gauge patient responses to a drug candidate.

  • In this partnership, technologies such as AI, radiomics, and data mining will be brought together by Median’s Imaging Lab division. This collaboration aims to extract digital signatures from images and deliver valuable insights into patient responses to the pharmaceutical company's drug candidate. These findings could serve as companion diagnostics, assisting in identifying those patients who are most likely to benefit from specific drugs.

  • Based in France, Median Technologies specializes in developing advanced medical imaging software and services for oncology clinical trials, cancer screening, and clinical practice. The company’s flagship product, eyonis, leverages AI to enhance early cancer detection. The company also offers imaging solutions through its iCRO business unit, supporting drug efficacy measurements in oncology clinical trials​.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.